Does Sleep Quality Change After Switch From Wellbutrin SR to Wellbutrin XL in Patients With Major Depressive Disorder?
Recruitment status was Active, not recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Wellbutrin (bupropion) is an effective antidepressant (Thase, M 2005). It exists in instant release (IR), sustained release (SR) and extended release (XL) forms. The IR formulation was never approved for use in Canada. The XL formulation allows for once daily dosing.
Wellbutrin is both a norepinephrine and dopamine reuptake inhibitor, and as such increases the synaptic concentration of both neurotransmitters. This adds to its positive effects on cognition, apathy, tiredness and executive functioning. The increased activation may be also responsible for some of its side effects such as initial insomnia and reduced sleep efficiency, especially when taken at night.
| Condition | Intervention | Phase |
|---|---|---|
|
Mood Disorder |
Drug: Wellbutrin XL |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Does Sleep Quality Change After Switch From Wellbutrin SR to Wellbutrin XL in Patients With Major Depressive Disorder? |
- This study is looking at the effect of Wellbutrin SR versus Wellbutrin XL on sleep quality [ Time Frame: pre, 3-5days, 3-4weeks after wellbutrinXL ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 15 |
| Study Start Date: | January 2007 |
| Estimated Study Completion Date: | January 2010 |
| Estimated Primary Completion Date: | January 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
1
Wellbutrin SR switched to Wellbutrin XL
|
Drug: Wellbutrin XL
Wellbutrin XL 300mg daily
Other Name: Bupropion
|
Detailed Description:
Wellbutrin SR formulation cannot be given as more than 150 mg as a single dose and higher doses are commonly required for the treatment of depression; they also have to be given at least 8 hours apart in order to avoid peak plasma concentrations and to reduce the risk of seizures (incidence of 0.1% at doses £ 300 mg). The twice a day dosing may result in complaints of insomnia and may necessitate discontinuing the medication or adding a sleep promoting agent. The benefit of once-daily dosing cannot be understated given treatment adherence is typically lower in depressed patients than their non-depressed counterparts; further, the 8 h dosing interval of bupropion SR is likely to have lower adherence compared with traditional bid dosing (i.e., morning and evening); thus, it is not difficult to imagine patients missing 30-50% of their second dose given the difficulty of recalling to take the second dose at work or school. The review of Fava et al. (2005) plots the relative PK profiles of XL and SR and notes the significantly lower bupropion concentration at bedtime, which is likely to reduce the occurrence of insomnia. Therefore, Wellbutrin XL may improve adherence by eliminating the second dose and Wellbutrin XL also avoids the high plasma drug concentrations at bedtime, as seen with bupropion SR, which are associated with insomnia. Further, the smoother pharmacokinetic profile of Wellbutrin XL may improve overall tolerability compared with Wellbutrin SR.
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Signed Patient Informed Consent;
- Patients with Major Depressive Disorders (DSM-IV-TR - criteria used);
- Out-patients;
- Males or females over 18 years of age;
- Patients currently using Wellbutrin SR.
Exclusion Criteria:
- Bipolar Disorder patients;
- Actively suicidal patients;
- Schizophrenia, Schizoaffective or other Psychotic Disorder;
- Pregnant women, as by pregnancy test at the beginning of the study;
- Women in childbearing age, refusing to use appropriate contraception, or breastfeeding mothers;
- Patients with known hypersensitivity to bupropion;
- Patients with severe or unstable medical conditions, which in the opinion of the investigator would interfere with their progress or safety;
- ECT or TMS treatments within the last three months;
- Patients who did not respond to previous treatment with bupropion;
- Patients with history of seizure disorder;
- Patients with history of eating disorders (e.g. bulimia, anorexia nervosa);
- Patients using sleep aiding medication (Benzodiazepines, barbiturates).
Contacts and Locations More Information
No publications provided
| Responsible Party: | Dr. Roumen Milev, Queen's University at Kingston |
| ClinicalTrials.gov Identifier: | NCT00616915 History of Changes |
| Other Study ID Numbers: | PSIY-219-05 |
| Study First Received: | February 4, 2008 |
| Last Updated: | February 10, 2009 |
| Health Authority: | Canada: Health Canada |
Keywords provided by Queen's University:
|
Wellbutrin SR |
Additional relevant MeSH terms:
|
Depressive Disorder Depression Depressive Disorder, Major Mood Disorders Mental Disorders Behavioral Symptoms Bupropion Antidepressive Agents, Second-Generation Antidepressive Agents Psychotropic Drugs |
Central Nervous System Agents Therapeutic Uses Pharmacologic Actions Dopamine Uptake Inhibitors Dopamine Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Neurotransmitter Uptake Inhibitors Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on June 17, 2013